Products & Pipeline 

Armstrong expects to utilize its research and development capabilities, both internally and through strategic alliances, to develop additional products utilizing its proprietary delivery systems. Armstrong’s Clinical Department performs clinical research to demonstrate the safety, performance, efficacy, and bioequivalence of its products.

Armstrong’s pipeline will continue to build upon its substantial experience in the development, manufacture and marketing (mainly in the U.S.) of inhaled respiratory drugs, primarily for bronchial asthma and chronic obstructive pulmonary disease (COPD), delivered by metered-dose inhalers. At the core of Armstrong’s efforts to grow its respiratory business is a continued investment in manufacturing capacity both for metered-dose inhalers and nasal sprays, which allow Armstrong to play an important role in all major markets where it operates.